Co-Targeting Leukemia-Initiating Cells and Leukemia Bulk Leads to Disease Eradication

Researchers studied acute promyelocytic leukemia (APLs) with different leukemia-initiating cells (LICs) frequencies and investigated the effect of two HDAC inhibitors: valproic acid, with relative selectivity towards class I HDAC enzymes and vorinostat/suberoylanilide hydroxamic acid in combination with all-trans retinoic acid, on the bulk APL cells and APL LICs.